Clinical Trial Update: A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating AIR001 for pulmonary arterial hypertension was terminated; no results are provided in the document.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• AIR001

Snippet

Sponsor: Aires Pharmaceuticals, Inc. | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: TERMINATED